NXT007(下一代活化因子VIII模拟双特异性抗体)在健康参与者中的首次人体研究
NXT007是模拟活化因子VIII辅因子功能的双特异性抗体,由艾美赛珠单抗改造而来。本研究在健康日本男性成人中开展首次人体单次递增剂量研究,40名参与者分5个队列随机接受单次皮下注射NXT007或安慰剂。结果显示NXT007耐受良好,无血栓事件,暴露呈剂量依赖性增加但低于剂量比例,抗药抗体阴性者消除半衰期约10周。
要点
- NXT007单次皮下注射耐受良好,未报告血栓事件或注射部位反应。
- 9名参与者产生抗NXT007抗体,均与NXT007清除加快相关但未影响安全性。
- 抗药抗体阴性参与者中NXT007消除半衰期约10周。
核心结论
- 单次皮下注射NXT007耐受良好且未发生血栓事件,其长半衰期、药理效应和安全性特征支持在血友病A患者中继续开展NXTAGE研究的后续多次递增剂量部分。
研究设计与样本
- 首次人体、单次递增剂量研究(NXTAGE研究A部分),在健康日本男性成人中开展。
- 共入组40名参与者,分5个队列,每队列随机接受单次皮下注射NXT007(每队列n=6;剂量为0.0018、0.0054、0.018、0.054或0.18 mg/kg)或安慰剂(每队列n=2)。
主要发现
- 不良事件发生率无剂量依赖性增加,未报告血栓事件或注射部位反应。
- 接受NXT007 0.0054 mg/kg的一名参与者报告1例严重不良事件(红斑),无法排除与NXT007的因果关系。
- 9名参与者产生抗NXT007抗体,均被认为与NXT007清除加快相关,但未影响安全性。
- NXT007暴露呈剂量依赖性增加,但增加幅度低于剂量比例。
- 在抗药抗体阴性参与者中,NXT007的消除半衰期约为10周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: NXT007 is a bispecific antibody that mimics the cofactor function of activated factor (F)VIII and was engineered by modifying emicizumab. Nonclinical investigations suggested its potential to provide nonhemophilic concentrations of coagulation activity to people with hemophilia A. A first-in-human, single-ascending dose study of NXT007 was conducted in healthy Japanese male adults (part A of the NXTAGE study). OBJECTIVES: To evaluate safety, immunogenicity, pharmacokinetics, and pharmacodynamics of NXT007. METHODS: Forty participants were enrolled across 5 cohorts and randomized to receive a single subcutaneous injection of NXT007 (n = 6 per cohort; 0.0018, 0.0054, 0.018, 0.054, or 0.18 mg/kg) or placebo (n = 2 per cohort). RESULTS: There were no dose-dependent increases in the incidence of adverse events, and no thrombotic events or injection-site reactions were reported. One serious adverse event of erythema was reported in a participant who received NXT007 0.0054 mg/kg, and its causality to NXT007 could not be ruled out. Nine participants developed anti-NXT007 antibodies; all were considered to be associated with faster clearance of NXT007 without impacting safety. NXT007 exposure increased dose-dependently but less than dose proportionally. The elimination half-life of NXT007 was approximately 10 weeks in antidrug antibody-negative participants. With ex vivo neutralization of endogenous FVIII in plasma samples, activated partial thromboplastin time was shortened, and thrombin generation was promoted in a dose-dependent manner. CONCLUSION: A single subcutaneous injection of NXT007 was well tolerated without occurrence of thrombotic events. The long half-life, pharmacological effect, and safety profile supported study progression to the subsequent multiple ascending dose parts of the NXTAGE study in people with hemophilia A.
引用
- Sambe T, Miwa T, Yoneyama K, et al. A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants. J Thromb Haemost. 2025. PMID: 40554054. doi:10.1016/j.jtha.2025.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。